




BRIDGE
TO A CURE
foundation



BRIDGE TO A CURE IS ON
A MISSION TO UNITE AND
TRANSFORM THE CHILDHOOD
CANCER RESEARCH COMMUNITY
TO REDUCE CHILDHOOD CANCER
DEATHS 50% BY 2030.

Table of Contents

2 Board of Directors

3 Letter from the President

4 Challenging the Status Quo

6 10 Years. 10 Milestones. 1 Mission.

7 History of Progress

8 The World’s Largest Data Resource

9 The M3 Approach to Scientific Discovery

10 Optimizing Discovery Platforms

11 Real-Time AI Infrastructure

12 Advances in Nontoxic Treatments

13 Preclinical Evidence & Momentum

14 Securing a Collaborative Research Ecosystem

15 National Investment & Federal Influence

15 The Blueprint for a Collaborative Cure

16 Donor Recognition

19 Financial Reporting

20 The Next Chapter

2025 LEADERSHIP

BOARD OF DIRECTORS

Robert Martin, Chair

Ken Asher, Secretary

David Gibbons, Treasurer

Winston Ely

Tricia Martin

Wendy Payton

Nan Smith

ADVISORY BOARD

Rudi Dubois

Ira Dunkel, MD

Henry Friedman, MD

Lois Juliber

Al Musella

Gary Tapella

Peter Tombros

Sandy Ward

MEMORANDUM

TO: Supporters, Partners, and Stakeholders

FROM: Office of the President, Bridge To A Cure Foundation

DATE: June 2026

SUBJECT: CASE UPDATE: A Decade of Difference

FIELD REPORT: THE CHALLENGE



Ten years ago, I discovered a systemic failure in pediatric medicine that had a tremendous impact on children. The status quo in pediatric brain tumor research was, by all accounts, a fragmented and broken system that hurt children regardless of the outcome. I found isolated institutions, siloed data, and a horrific lack of progress that cost children bright futures. The vision for Bridge To A Cure Foundation, presented to the National Cancer Institute (NCI) on October 5, 2017, was not just a plan; it was an indictment of the way things were and a framework for the way they must become.

EVIDENCE OF PROGRESS

This 2025 Annual Report, titled "A Decade of Difference," serves to showcase how the system is changing and how, over the last 10 years, our investments, influence, and activism have dismantled the barriers to discovery and created an environment of accelerated paths toward meaningful progress for pediatric brain tumor research. You will learn about:

- The world's largest pediatric brain tumor data resource is now accessible to researchers globally.
- Adoption of the M3 approach, integrating biology, diverse data types, and multidisciplinary expertise to form a more complete view of a child's health.
- The deployment of the Real-time Analysis and Discovery in Integrated And Networked Technologies (RADIANT) project, an AI-empowered infrastructure that bridges the gap between raw data and clinical science.
- Replacing the failed and horrific standard of care treatment with nontoxic treatments.

THE INVESTIGATION CONTINUES

Our work is not yet completed, but it exemplifies the progress we promised more than 10 years ago. Over this period, Bridge To A Cure has generated more than \$1.5M in philanthropic funding and helped unite 35 collaborating institutions to accelerate the search for nontoxic, precision treatments, which remains our highest priority.

NEW OPERATIONAL DIRECTIVE

To scale our impact, the Bridge To A Cure Foundation is officially joining forces with the Children's Brain Tumor Network (CBTN). This is a strategic move that will allow us to sustain the mission. The evidence is clear: Collaboration is the fastest path to a cure. We thank you for standing with us as visionary explorers on this journey.

Together for Kids,

Robert Martin, Founder & President



Clara

EXHIBIT A:

CHALLENGING THE STATUS QUO

Background

The investigation began with a journey that exposed a broken system. For decades, pediatric brain tumor research was crippled by fragmented data, limited collaboration, a lack of tools, and stagnated progress. The toxic treatments generally prescribed for adults have failed at every level, posing long-term health risks for children.

On October 5, 2017, just three days before the passing of his granddaughter, Clara, Bob Martin presented a strategic framework to the National Cancer Institute detailing a **different approach** that would serve as the blueprint for how science, technology, and data could bridge the gap between terminal diagnoses and actual cures.

THE STRATEGY WAS DRIVEN BY THREE IMPERATIVES:

DATA & AI

Unlocking discovery by sharing data and applying advanced technology.

NONTOXIC TREATMENTS

Accelerating the search for safer therapies; treatments that aren't horrifically painful, ineffective, and harmful to the entire family.

COLLABORATION

Uniting the global pediatric brain tumor research community.



EXHIBIT B:
PROGRESS OVERVIEW

MISSION DEBRIEF

The investigation into the last decade confirms that Bridge To A Cure has executed a multifront approach to transform childhood brain tumor research. The strategy is built upon Bridge To A Cure’s strategic approach across three critical areas of influence:

Imperative 1:
DATA & AI

Unlocking discovery by sharing data and applying advanced technology.

- **PROGRESS**
Researchers now access large, integrated datasets and analyze them with artificial intelligence to more easily identify patterns that lead to new treatments faster than ever before.

Imperative 2:
NONTOXIC TREATMENTS

Accelerating the search for safer therapies.

- **PROGRESS**
Children deserve treatments that save lives without compromising future quality of life. Nontoxic treatments are essential to this objective. Precision medicine is becoming the standard of care.

Imperative 3:
COLLABORATION

Uniting the global pediatric brain tumor research community.

- **PROGRESS**
Researchers within the childhood brain tumor community are quickly abandoning the old model of working in silos and embracing a shared learning, shared data, collaborative approach.

Strategy That Drives Progress
10 Years
10 Milestones
1 Mission

EXHIBIT C:

JOURNEY HIGHLIGHTS
(Verified Data)

The following metrics have been recovered from the field to quantify the **Decade of Difference**:

✓ Secured Funding
\$1.5M in philanthropic funding via Bridge To A Cure

✓ Active Network
35 collaborating institutions and 20+ peer childhood cancer foundations

✓ Assets
Millions of shared data points and 88 thousand tumor specimens

✓ Biological Models:
50 preclinical models created

✓ Field Personnel
Thousands of researchers accessing shared resources

A History of Progress

2016: Clara diagnosed on St. Patrick's Day

2017: Bridge To A Cure Foundation established; meets with NCI director to lay out imperatives

2018: Call to the community: investors, donors, government, practitioners, educators

2019: Foundation teams with the Volchenbom Lab to standardize research data language

2020: Bridge To A Cure advances the formation of the NCI Childhood Cancer Database Initiative (CCDI)

2021: Bridge To A Cure joins CBTN Executive Council

2022: Foundation drives data collection, storage, and access

2023: Bridge To A Cure fuels CBTN's Project Accelerate for faster breakthroughs

2024: Bridge To A Cure sets the stage for pediatric brain tumor Generative AI platform

2025: Bridge To A Cure drives first glioblastoma scientific conference with Stand Up 2 Cancer

2026: Bridge To A Cure Integrates with CBTN



EXHIBIT D: THE WORLD'S LARGEST DATA RESOURCE

Milestone #1

BUILDING THE FOUNDATION OF DISCOVERY

The Bridge To A Cure framework requires that shared data resources be the primary engine driving transformation in pediatric brain tumor research. The Pediatric Brain Tumor Atlas (PBTA), created by the CBTN, has built the world's largest childhood brain tumor data repository, integrating clinical and genetic intelligence.

It's a massive dataset with more than a million data points driving the development of new treatments for pediatric brain tumors. Since 2024, the CBTN PBTA has been housed at the NIH-funded Gabriella Miller Kids First Data Resource Center (Kids First DRC), where researchers use robust tools to cross-reference PBTA data with 34 other pediatric and rare disease datasets.

OPERATIONAL PROTOCOL: Data and resources are available to academic researchers globally at no charge. Bridge To A Cure funded the processing of a 900-patient high-grade glioma (HGG) dataset to exceed the FDA gold standard for research assets.

INTELLIGENCE IMPACT: Once processed, this dataset will be used in AI research for one of the most aggressive forms of childhood brain tumors, directly accelerating the pace of discovery.



EXHIBIT E: THE M3 APPROACH TO SCIENTIFIC DISCOVERY

Milestone #2

UNIFIED DATA INTELLIGENCE

The new CBTN M3 research approach advanced by Bridge To A Cure leverages data, technology, and diverse disciplines rather than relying on siloed medical disciplines working in parallel. It has become the new standard in pediatric research, not just for brain tumors, but also across a wide array of congenital conditions.

MULTIOMIC ANALYSIS: Integrating data from multiple biological layers (genomics, proteomics, transcriptomics, epigenomics, and metabolomics) to create a holistic view of patient health.

MULTIMODAL INTEGRATION: Merging different data types, including MRI/PET imaging, clinical data, and molecular/genetic data, to improve diagnostic accuracy.

MULTIDISCIPLINARY COOPERATION: Aligning expertise across oncology, pathology, genetics, neurology, and psychiatry.

EXHIBIT F:

OPTIMIZING DISCOVERY PLATFORMS

Milestone #3

CLOUD-BASED SCIENTIFIC ACCELERATION

Large-scale datasets, when paired with powerful cloud computing and cross-institutional investigation, effectively bypass traditional research bottlenecks. The ability to forge strong partnerships with innovative organizations is the backbone of this global intelligence network. The following platforms supported by Bridge To A Cure connect researchers with the tools, insights, and skills to accelerate pediatric brain tumor research:

CCDI

Childhood Cancer Data Initiative

A national strategy, promoted by Bridge To A Cure, facilitates data sharing and collect data from every child, adolescent, and young adult with cancer, regardless of where they are treated.

CPTAC

Clinical Proteomic Tumor Analysis Consortium

A National Institute of Health (NIH) effort to accelerate large-scale studies of genes and proteins to understand how cancer works.

Kids First

(Gabriella Miller Kids First Data Resource Center)

A large-scale data repository focused on discovering the genetic pathways shared between childhood cancers and structural disorders.

CBTN Preclinical Models Portal

A specialized gateway providing investigators with access to biological models required to test new therapeutic hypotheses before they reach the clinical stage.

Flywheel

A biomedical research data management platform that streamlines the ingestion, classification, and analysis of complex imaging data.

The raw data generated by these platforms requires sophisticated tools to develop actionable insights. The two primary tools created for high-level forensic analysis of pediatric brain tumors are:

CAVATICA: A cloud-based data analysis platform that allows researchers to collaboratively analyze, share, and store massive genomic datasets in real time.

PEDCBIOPORTAL: Designed specifically for the pediatric research community to visualize and analyze complex cancer data.

EXHIBIT G:

REAL-TIME AI INFRASTRUCTURE

Milestone #4

AI-DRIVEN INFRASTRUCTURE THROUGH RADIANT

To explore how artificial intelligence (AI) can accelerate all aspects of the research process, Bridge To A Cure invested in a patient data pipeline that enables real-time, AI-driven inquiry. Real-time Analysis and Discovery in Integrated And Networked Technologies (RADIANT) is going to change how doctors can better serve their patients. Due to a \$50M investment from a federal science agency in 2025, its infrastructure is projected to be in 200 US pediatric hospitals within the next three years.

PIONEERING INVESTMENT: Bridge To A Cure helped to fund the development of a patient data pipeline, enabling AI-driven inquiry.

FIELD CAPABILITIES: The platform utilizes federated data networks and real-time clinical integration to optimize personalized, precise treatments.

OPERATIONAL EXPANSION: Accelerated by a \$50M ARPA-H investment, this infrastructure is scheduled to be deployed in 200 US pediatric hospitals by 2030.



EXHIBIT H:

ADVANCES IN NONTOXIC TREATMENTS

STRATEGIC OBJECTIVE: AI-empowered molecular tumor classification is now guiding more informed, individualized therapy strategies.

VERIFIED ASSETS:

50 PRECLINICAL MODELS: Created to accelerate pediatric drug development by pharmaceutical partners so they can evaluate treatments with higher speed and accuracy.

NEW THERAPEUTIC PATHWAYS: Momentum is building around immunotherapy, apoptosis pathways, and targeted therapies to improve quality of life for survivors.



Milestone #5

ACCELERATING TARGETED CARE FOR CHILDREN

The transition from broad-spectrum treatments to individualized strategies is well underway, thanks in part to the Bridge To A Cure support for technological solutions to roadblocks that have long plagued pediatric research. This shift helps doctors to leverage AI to identify cancer types and choose the right treatments.

This leads to:

INDIVIDUALIZED THERAPY: Tactical shifts toward therapy strategies tailored to the specific genetic makeup of an individual child's tumor.

TARGETED APPROACHES: Implementation of treatment methods designed to attack cancer cells while sparing healthy tissue.

REAL-TIME INTELLIGENCE: Researchers now have accelerated access to data that informs immediate care adjustments.



EXHIBIT I:

PRECLINICAL EVIDENCE & MOMENTUM

Milestone #6

EXPANDING THE TESTING INFRASTRUCTURE: To ensure the safety of new protocols before they reach the field, the foundation has supported a massive expansion of testing assets.

ASSET COUNT: With support from Bridge To A Cure, CBTN has partnered with major pharmaceutical companies to develop robust control-arm testing using the PBTA data, which prevents placebo treatments from being used on pediatric patients. In addition to developing pre-clinical models, CBTN is developing drug testing on tumoroids to help drug developers cultivate effective, nontoxic treatments more safely and more quickly.

OPERATIONAL BENEFIT: These models allow investigators to evaluate the efficacy of new treatments with significantly higher speed and accuracy.

Milestone #7

ADVANCING NEW THERAPEUTIC PATHWAYS

The main goal of accelerating research for children diagnosed with brain tumors is to explore and identify effective treatments that don't cause long-term toxicity in patients. To that end, Bridge To A Cure has pushed research toward:

IMMUNOTHERAPY: Leveraging the body's own biological defenses.

APOPTOSIS PATHWAYS: Engineering protocols that trigger the natural self-destruction of malignant cells.

TARGETED THERAPIES: Refining the precision of medical "strikes" against tumor growth.



EXHIBIT J:

SECURING A COLLABORATIVE RESEARCH ECOSYSTEM

Milestone #8

BREAKING THE INSTITUTIONAL SILO

Bridge To A Cure Foundation was instrumental in shifting pediatric brain tumor research away from isolated, competitive models toward a unified, shared discovery framework.

Key operational partners identified in this network include:



EXHIBIT K:

NATIONAL INVESTMENT & FEDERAL INFLUENCE

Milestone #9

SHAPING POLICY AND FUNDING

For a decade now, Bridge To A Cure Foundation operated as a high-level advocate, building momentum for increased federal investment in pediatric health. Through both economic and foundational support, Bridge To A Cure fostered the environment that made collaboration and nontraditional research programs possible.

Here are some examples of how Bridge To A Cure helped promote a more effective approach to research:

KIDS FIRST DATA RESOURCE CENTER: Partnered to create highly targeted awareness and letter-writing campaigns of support for this vital pediatric research ecosystem.

CHILDHOOD CANCER DATA INITIATIVE (CCDI): An early advocate for a unified pediatric cancer database, CCDI now provides pediatric research data sourced from seven of the largest data ecosystems, including the Gabriella Miller Kids First Data Resource Center, and St. Jude's Cloud.

ARPA-H INITIATIVES: Supported through formal organizational letter writing campaigns, public advocacy, and financial investment in data pipeline developments.

EXHIBIT L:

THE BLUEPRINT FOR A COLLABORATIVE CURE

Milestone #10

OPERATIONAL SUSTAINABILITY

Participation in the CBTN Executive Council since 2021 has provided research institutions with a road map for curing rare diseases through radical cooperation.

DIRECT INVESTMENT: Capital investments by Bridge To A Cure dedicated to the sustainability of CBTN operations.

PAID

STRATEGIC OUTCOME: This investment secured deeper integration between Bridge To A Cure and CBTN, ensuring that the research infrastructure remains operational and accessible for years to come.

KNOWN ASSOCIATES:

Donor Recognition

Daniel Adler	Bob & Cathy Curt	Jacoff Foundation
Ken & Gwen Asher	Ann Deming	Jon Jones
Dick & Jan Bean	Larry Den	Lois Juliber
Jerry & Sarah Jane Bear	Peter Donohoe	John & Elaine Kanas
Bob & Cindy Brazier	Tracy & Peter Drippe	Elliot & Donna Katzman
Colette & Jeffrey Brazier	Charles & Judy Eaton	Fred Kaynor
Charles Brighton	Winston Ely	Bryan Kelley
Tom & Pat Callans	Stan Epperson	Tom & Patty King
Charlene Caprio	John Faul	Jessie Krafft
Thomas Catherall	Debra Feeks	Richard & Cathy Krauss
Henry Cavanna	Angela George	Susan Lobdell
Louise Cecchini	David Gibbons	Kevin MacGuire
Fran & Tony Ciarnapaglio	Wouter Goedkoop	James & Lynn Major
Malin & Will Clyde	Charlie & Mary Ann Goodin	Vito & Linda Manone
Ian Cook	David Groener	Dan & Susan Mariani
Catherine & Kenneth Corwen	Janienne Hackett	Reuben Mark
John & Carol Courtney	Lynne Hochstadt	Tony & Gillian Mark
Lori Cullen	Ernie & Paula Horvath	Gene & Bonnie Markowski
Diane Curry	Parke & Sally Jackson	Bob & Pam Martin

With gratitude, we acknowledge the patrons who have made an impact on accelerating pediatric brain tumor research and the efforts of Bridge To A Cure Foundation in 2025.

Deborah Martin	Wendy Payton	Vikram Taneja
Tricia Martin	Jim & Gail Rand	Gary & Karen Tapella
Nicholas Maurillo	Glen & Pat Rauch	Steve & Susa Teitelman
Dan Mazabras	Gunther Reese	Javier Tervel
John & Judy McCarty	Douglas & Julie Reid	Peter & Ann Tombros
David & Suzanne McCollum	Mike & Erin Rhodes	Stephen Wagner
BessCatherine McCord	Thomas Riley	Stevenson & Sandy Ward
Ray & Judy McGuire	Carolyn Rogers	Michael & Holly Watts
Katharine McLeod	Jack Rogers	Ruth Whitley
Ed & Sharon Montero	Craig & Lois Rohner	Janet Wilkinson
John & Neicey Morre	Tom & Mary Jane Ross	Gary & Jacque Wolken
Stephen Moskowitz	Chip & Susan Schroeder	Jeff & Sheri Wright
Kathleen Moss	Jim & Stephanie Seaborg	Peg Yardis
Frannie Moyer	Maren & Frank Sharpe	
Jeffrey Muddell	Patricia & Nick Sheridan	
Bob & Fran Murray	Martin Sherman	
Peter & Judy Nance	Mike & Audrey Sherman	
Tuck & Beth Nason	Charlie & Mapes Stamm	
Jeff Neubert	Rick & Christine Stone	
Thomas & Celeste Niarchos	Warren (Jay) Strausser	
Jon & Janet Olmstead	Kathie Streep	
Jack Pallotta	Charlotte & John Suhler	



Financial Reporting

	TOTAL
REVENUE AND SUPPORT	
Donations*	\$ 349,000
TOTAL REVENUE AND SUPPORT	349,000
EXPENSES	
Program Services	282,000
Management & General Services	39,000
Fundraising Services	28,000
TOTAL EXPENSES	349,000
NONOPERATING ACTIVITIES	
CHANGE IN NET ASSETS	[9,000]
NET ASSETS, START OF YEAR	83,000
NET ASSETS, END OF YEAR	\$ 74,000

Bridge To A Cure Foundation has operated as a 501(c)3 nonprofit charitable organization since its incorporation in September 2019.



FIELD UPDATE

The investigation is entering a new phase as Bridge To A Cure formally integrates with CBTN, which has demonstrated over time that it is well positioned to drive research toward cures, aligning with the core Bridge To A Cure mission.

This tactical merger is designed to:

Scale Impact

Expanding the reach of proven research models and resources

Ensure Stewardship

Bridge To A Cure leadership will maintain its involvement in the HGG Data Project and continue its role in providing strategic guidance as a member of the CBTN Executive Council

Secure the Future

The establishment of the CBTN Bridge To A Cure Fund allows supporters to finance the next decade of investigative discovery

DONATE

Thanks to the generosity of many, progress is accelerating. But children with brain cancer are still waiting for better answers. Your support can help move promising science closer to the cures they urgently need. Give once or give monthly at BridgeToACure.org.

For other ways to give, visit the website's support page to see check, stock, wire, employer matching, or legacy giving options.

CONNECT



@BTACFoundation

Visit BridgeToACure.org/support or call 239.469.1755 to learn more.

BRIDGE TO A CURE FOUNDATION, INC.
bridgetoacure.org • 239.469.1755